Your Daily Pharmaceuticals Briefing
Drug approvals, clinical trials, pricing debates, and the pharmaceutical industry landscape. Get the latest pharmaceuticals developments delivered to your inbox every morning. AI-powered, personalized, and grounded in real sources.
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide) for Polycythemia Vera
Takeda announced on August 28, 2026, that the U.S. Food and Drug Administration (FDA) approved MIMRYLO™ (rusfertide) for treating erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This first-in-class hepcidin mimetic is designed to regulate iron distribution and red blood cell overproduction to control hematocrit levels, marking a potential shift in the treatment paradigm for PV.
Formosa Pharmaceuticals submitted a clinical trial application (CTA) to European regulators on August 28, 2026, to initiate a pivotal trial for TSY-110. This proposed biosimilar aims to be the first alternative to Roche's ado-trastuzumab emtansine (Kadcyla), a HER2 breast cancer therapy that generated approximately $2.5 billion in global sales in 2025.
The Bottom Line
Recent pharmaceutical developments highlight a continued focus on targeted therapies for rare diseases and oncology, alongside strategic moves in biosimilar development and long-term efficacy data for existing treatments. The rapid approval pathways and significant survival benefits underscore the industry's drive to address unmet medical needs.
Get Pharmaceuticals in your inbox every morning
Join readers who start their day with an AI-powered briefing on pharmaceuticals and the topics they care about most — fully sourced and ready in 5 minutes.
Start your free trial7-day free trial · No credit card required
Related Briefings
Pick your topics
Pharmaceuticals, plus anything else you follow
We research overnight
AI synthesizes real-time sources while you sleep
Read in 5 minutes
Cited, structured, no fluff — in your inbox every morning